ArticleiScience2026
SARS-CoV-2 infects olfactory neurons and basal stem cells and induces axonal degeneration through TRPV1 activation.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurological complications such as anosmia are among the most frequent and persistent symptoms of COVID-19; yet, the mechanisms linking SARS-CoV-2 infection to sensory neuronal injury remain unclear. We demonstrate that SARS-CoV-2 directly infects olfactory sensory neurons through ACE2 upregulation and stimulates basal stem cell proliferation, as shown in human iPSC-derived sensory neurons and validated in golden Syrian hamsters. Exposure to live viruses or its S1 spike protein induces TRPV1 channel redistribution from the nucleus to the plasma membrane, resulting in axonal degeneration. Single-nucleus RNA sequencing reveals activation of exocytosis and transmembrane transport pathways with disruption of axonal guidance networks. Pharmacological inhibition of TRPV1 with capsazepine mitigates neuronal injury and preserves axonal integrity. These findings identify TRPV1 activation as a central mediator of SARS-CoV-2-induced neurodegeneration in the olfactory epithelium and suggest that TRPV1 antagonism offers a promising therapeutic avenue for treating COVID-19-related anosmia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.